Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13042904 | 0.95 | MMP12 (0.34) | MMP12FFAR1POLB | |
| SCHEMBL15761478 | 0.85 | FFAR1 (0.38) | FFAR1ALDH1A1 | |
| SCHEMBL786860 | 0.84 | NPC1 (0.30) | SMN1; SMN2NPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL14586568 | 0.84 | NPC1 (0.30) | SMN1; SMN2NPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL786925 | 0.83 | CACNA2D1 (0.39) | — | |
| SCHEMBL13042932 | 0.78 | MMP12 (0.31) | MMP12 | |
| SCHEMBL13042907 | 0.76 | CPA1 (0.41) | MMP12 | |
| SCHEMBL13042911 | 0.76 | CACNA2D1 (0.35) | SMN1; SMN2 | |
| SCHEMBL13042868 | 0.73 | CACNA2D1 (0.33) | — | |
| SCHEMBL15761479 | 0.71 | FFAR1 (0.33) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166342-A1 | Functionalized Matrices for Dispersion of Nanostructures | NANOSYS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20130043433-A1 | Functionalized Matrixes for Dispersion of Nanostructures | NANOSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120068118-A1 | NANOCRYSTAL DOPED MATRIXES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120068118-A1 | NANOCRYSTAL DOPED MATRIXES | STRA6, EPHA6, PIR | SMN1; SMN2 1562/4885NPC1 3609/4885RAB9A 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.